Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke
To evaluate the risks of recurrent stroke and major bleeding events with clopidogrel and aspirin use among patients aged 80 years or older. This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan. Patients aged 80 years or older who r...
Gespeichert in:
| Veröffentlicht in: | Mayo Clinic proceedings 2022-08, Vol.97 (8), p.1483-1492 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1492 |
|---|---|
| container_issue | 8 |
| container_start_page | 1483 |
| container_title | Mayo Clinic proceedings |
| container_volume | 97 |
| creator | Huang, Hsin-Yi Lin, Shin-Yi Katz, Aaron J. Sheu, Jau-Jiuan Lin, Fang-Ju Wang, Chi-Chuan Wu, Chung-Hsuen |
| description | To evaluate the risks of recurrent stroke and major bleeding events with clopidogrel and aspirin use among patients aged 80 years or older.
This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan. Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included. Inverse probability of treatment weighting was used to balance measured covariates between clopidogrel and aspirin users. Measured outcomes included recurrent acute ischemic stroke, acute myocardial infarction, composite cardiovascular events (recurrent stroke or acute myocardial infarction), intracranial hemorrhage, major gastrointestinal tract bleeding, and composite major bleeding events (intracranial hemorrhage or major gastrointestinal tract bleeding).
A total of 15,045 patients were included in the study, 1979 of whom used clopidogrel and 13,066 who used aspirin following hospitalization for primary acute ischemic stroke. Clopidogrel use was associated with significantly lower risk of recurrent acute ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.83 to 0.96; P=.002), composite cardiovascular events (HR, 0.88; 95% CI, 0.82 to 0.95; P |
| doi_str_mv | 10.1016/j.mayocp.2022.01.033 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2699703026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743413826</galeid><els_id>S0025619622000696</els_id><sourcerecordid>A743413826</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-c6965dee1c2698138f707f103f39725033b458701719028ab193d3e95ca6c9f63</originalsourceid><addsrcrecordid>eNp9UU1rGzEQFaWBukn_QQ86lV52O5L2w7oUjHHaQKCBtPTQg1C0o1iuvNpKssH_PnI3h-ZSZmBgeO_xZh4h7xnUDFj3aVfv9SmYqebAeQ2sBiFekQWTDa_atulekwUAb6uOye4NeZvSDgB6KZsF-bWxFk12RxwxJarHgd5ri_lEg6VrHyY3hMeInh4TXaXJRTfS0hs_YPQneqezwzEn-tPlLb1JZot7Z-h9juE3XpELq33Cd8_zkvy43nxff61uv325Wa9uK9OAzJXpZNcOiMzwTi6ZWNoeestAWCF73pZbHpp22QPrmQS-1A9MikGgbI3ujLSduCQfZ90phj8HTFntXTLovR4xHJIqsrIHAfwMrWfoo_ao3GhDjtqUGs6-w4jWlf2qb0RTjPwlfPiHsEXt8zYFf8gujOklsJmBJoaUIlo1RbfX8aQYqHNKaqfmlNQ5JQVMlcsK7fNMw_Kgo8OokikfNTi4WHJRQ3D_F3gCCKSa1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699703026</pqid></control><display><type>article</type><title>Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke</title><source>Alma/SFX Local Collection</source><creator>Huang, Hsin-Yi ; Lin, Shin-Yi ; Katz, Aaron J. ; Sheu, Jau-Jiuan ; Lin, Fang-Ju ; Wang, Chi-Chuan ; Wu, Chung-Hsuen</creator><creatorcontrib>Huang, Hsin-Yi ; Lin, Shin-Yi ; Katz, Aaron J. ; Sheu, Jau-Jiuan ; Lin, Fang-Ju ; Wang, Chi-Chuan ; Wu, Chung-Hsuen</creatorcontrib><description>To evaluate the risks of recurrent stroke and major bleeding events with clopidogrel and aspirin use among patients aged 80 years or older.
This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan. Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included. Inverse probability of treatment weighting was used to balance measured covariates between clopidogrel and aspirin users. Measured outcomes included recurrent acute ischemic stroke, acute myocardial infarction, composite cardiovascular events (recurrent stroke or acute myocardial infarction), intracranial hemorrhage, major gastrointestinal tract bleeding, and composite major bleeding events (intracranial hemorrhage or major gastrointestinal tract bleeding).
A total of 15,045 patients were included in the study, 1979 of whom used clopidogrel and 13,066 who used aspirin following hospitalization for primary acute ischemic stroke. Clopidogrel use was associated with significantly lower risk of recurrent acute ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.83 to 0.96; P=.002), composite cardiovascular events (HR, 0.88; 95% CI, 0.82 to 0.95; P<.001), intracranial hemorrhage (HR, 0.71; 95% CI, 0.56 to 0.90; P=.005), and composite major bleeding events (HR, 0.89; 95% CI, 0.80 to 0.99; P=.04) compared with aspirin use.
In patients aged 80 years or older with primary acute ischemic stroke, clopidogrel users had lower risks of recurrent stroke and the composite cardiovascular events compared with aspirin users. Clopidogrel users also had lower risks of intracranial hemorrhage and the composite major bleeding events compared with aspirin users.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2022.01.033</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Aged ; Aspirin ; Clopidogrel ; Complications and side effects ; Health aspects ; Patient outcomes</subject><ispartof>Mayo Clinic proceedings, 2022-08, Vol.97 (8), p.1483-1492</ispartof><rights>2022 Mayo Foundation for Medical Education and Research</rights><rights>COPYRIGHT 2022 Elsevier, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-c6965dee1c2698138f707f103f39725033b458701719028ab193d3e95ca6c9f63</citedby><cites>FETCH-LOGICAL-c409t-c6965dee1c2698138f707f103f39725033b458701719028ab193d3e95ca6c9f63</cites><orcidid>0000-0002-7319-6644 ; 0000-0003-0495-1922</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Huang, Hsin-Yi</creatorcontrib><creatorcontrib>Lin, Shin-Yi</creatorcontrib><creatorcontrib>Katz, Aaron J.</creatorcontrib><creatorcontrib>Sheu, Jau-Jiuan</creatorcontrib><creatorcontrib>Lin, Fang-Ju</creatorcontrib><creatorcontrib>Wang, Chi-Chuan</creatorcontrib><creatorcontrib>Wu, Chung-Hsuen</creatorcontrib><title>Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke</title><title>Mayo Clinic proceedings</title><description>To evaluate the risks of recurrent stroke and major bleeding events with clopidogrel and aspirin use among patients aged 80 years or older.
This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan. Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included. Inverse probability of treatment weighting was used to balance measured covariates between clopidogrel and aspirin users. Measured outcomes included recurrent acute ischemic stroke, acute myocardial infarction, composite cardiovascular events (recurrent stroke or acute myocardial infarction), intracranial hemorrhage, major gastrointestinal tract bleeding, and composite major bleeding events (intracranial hemorrhage or major gastrointestinal tract bleeding).
A total of 15,045 patients were included in the study, 1979 of whom used clopidogrel and 13,066 who used aspirin following hospitalization for primary acute ischemic stroke. Clopidogrel use was associated with significantly lower risk of recurrent acute ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.83 to 0.96; P=.002), composite cardiovascular events (HR, 0.88; 95% CI, 0.82 to 0.95; P<.001), intracranial hemorrhage (HR, 0.71; 95% CI, 0.56 to 0.90; P=.005), and composite major bleeding events (HR, 0.89; 95% CI, 0.80 to 0.99; P=.04) compared with aspirin use.
In patients aged 80 years or older with primary acute ischemic stroke, clopidogrel users had lower risks of recurrent stroke and the composite cardiovascular events compared with aspirin users. Clopidogrel users also had lower risks of intracranial hemorrhage and the composite major bleeding events compared with aspirin users.</description><subject>Aged</subject><subject>Aspirin</subject><subject>Clopidogrel</subject><subject>Complications and side effects</subject><subject>Health aspects</subject><subject>Patient outcomes</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UU1rGzEQFaWBukn_QQ86lV52O5L2w7oUjHHaQKCBtPTQg1C0o1iuvNpKssH_PnI3h-ZSZmBgeO_xZh4h7xnUDFj3aVfv9SmYqebAeQ2sBiFekQWTDa_atulekwUAb6uOye4NeZvSDgB6KZsF-bWxFk12RxwxJarHgd5ri_lEg6VrHyY3hMeInh4TXaXJRTfS0hs_YPQneqezwzEn-tPlLb1JZot7Z-h9juE3XpELq33Cd8_zkvy43nxff61uv325Wa9uK9OAzJXpZNcOiMzwTi6ZWNoeestAWCF73pZbHpp22QPrmQS-1A9MikGgbI3ujLSduCQfZ90phj8HTFntXTLovR4xHJIqsrIHAfwMrWfoo_ao3GhDjtqUGs6-w4jWlf2qb0RTjPwlfPiHsEXt8zYFf8gujOklsJmBJoaUIlo1RbfX8aQYqHNKaqfmlNQ5JQVMlcsK7fNMw_Kgo8OokikfNTi4WHJRQ3D_F3gCCKSa1g</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Huang, Hsin-Yi</creator><creator>Lin, Shin-Yi</creator><creator>Katz, Aaron J.</creator><creator>Sheu, Jau-Jiuan</creator><creator>Lin, Fang-Ju</creator><creator>Wang, Chi-Chuan</creator><creator>Wu, Chung-Hsuen</creator><general>Elsevier Inc</general><general>Elsevier, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7319-6644</orcidid><orcidid>https://orcid.org/0000-0003-0495-1922</orcidid></search><sort><creationdate>202208</creationdate><title>Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke</title><author>Huang, Hsin-Yi ; Lin, Shin-Yi ; Katz, Aaron J. ; Sheu, Jau-Jiuan ; Lin, Fang-Ju ; Wang, Chi-Chuan ; Wu, Chung-Hsuen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-c6965dee1c2698138f707f103f39725033b458701719028ab193d3e95ca6c9f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Aspirin</topic><topic>Clopidogrel</topic><topic>Complications and side effects</topic><topic>Health aspects</topic><topic>Patient outcomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Hsin-Yi</creatorcontrib><creatorcontrib>Lin, Shin-Yi</creatorcontrib><creatorcontrib>Katz, Aaron J.</creatorcontrib><creatorcontrib>Sheu, Jau-Jiuan</creatorcontrib><creatorcontrib>Lin, Fang-Ju</creatorcontrib><creatorcontrib>Wang, Chi-Chuan</creatorcontrib><creatorcontrib>Wu, Chung-Hsuen</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Hsin-Yi</au><au>Lin, Shin-Yi</au><au>Katz, Aaron J.</au><au>Sheu, Jau-Jiuan</au><au>Lin, Fang-Ju</au><au>Wang, Chi-Chuan</au><au>Wu, Chung-Hsuen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke</atitle><jtitle>Mayo Clinic proceedings</jtitle><date>2022-08</date><risdate>2022</risdate><volume>97</volume><issue>8</issue><spage>1483</spage><epage>1492</epage><pages>1483-1492</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><abstract>To evaluate the risks of recurrent stroke and major bleeding events with clopidogrel and aspirin use among patients aged 80 years or older.
This retrospective cohort study was conducted using the Full Population Data of the Health and Welfare Database in Taiwan. Patients aged 80 years or older who received monotherapy with clopidogrel or aspirin following hospitalization for primary acute ischemic stroke between January 1, 2009, and December 31, 2018, were included. Inverse probability of treatment weighting was used to balance measured covariates between clopidogrel and aspirin users. Measured outcomes included recurrent acute ischemic stroke, acute myocardial infarction, composite cardiovascular events (recurrent stroke or acute myocardial infarction), intracranial hemorrhage, major gastrointestinal tract bleeding, and composite major bleeding events (intracranial hemorrhage or major gastrointestinal tract bleeding).
A total of 15,045 patients were included in the study, 1979 of whom used clopidogrel and 13,066 who used aspirin following hospitalization for primary acute ischemic stroke. Clopidogrel use was associated with significantly lower risk of recurrent acute ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.83 to 0.96; P=.002), composite cardiovascular events (HR, 0.88; 95% CI, 0.82 to 0.95; P<.001), intracranial hemorrhage (HR, 0.71; 95% CI, 0.56 to 0.90; P=.005), and composite major bleeding events (HR, 0.89; 95% CI, 0.80 to 0.99; P=.04) compared with aspirin use.
In patients aged 80 years or older with primary acute ischemic stroke, clopidogrel users had lower risks of recurrent stroke and the composite cardiovascular events compared with aspirin users. Clopidogrel users also had lower risks of intracranial hemorrhage and the composite major bleeding events compared with aspirin users.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.mayocp.2022.01.033</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-7319-6644</orcidid><orcidid>https://orcid.org/0000-0003-0495-1922</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-6196 |
| ispartof | Mayo Clinic proceedings, 2022-08, Vol.97 (8), p.1483-1492 |
| issn | 0025-6196 1942-5546 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2699703026 |
| source | Alma/SFX Local Collection |
| subjects | Aged Aspirin Clopidogrel Complications and side effects Health aspects Patient outcomes |
| title | Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A10%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20Safety%20of%20Clopidogrel%20vs%20Aspirin%20in%20Elderly%20Patients%20With%20Ischemic%20Stroke&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Huang,%20Hsin-Yi&rft.date=2022-08&rft.volume=97&rft.issue=8&rft.spage=1483&rft.epage=1492&rft.pages=1483-1492&rft.issn=0025-6196&rft.eissn=1942-5546&rft_id=info:doi/10.1016/j.mayocp.2022.01.033&rft_dat=%3Cgale_proqu%3EA743413826%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2699703026&rft_id=info:pmid/&rft_galeid=A743413826&rft_els_id=S0025619622000696&rfr_iscdi=true |